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Secnidazole is an antimicrobial agent used primarily in the treatment of amoebiasis. For this bioequivalence 
study of secnidazole, twenty-eight healthy female volunteers were enrolled in a randomized crossover 
study. Each volunteer was given a single oral dose of secnidazole test preparation and then the reference 
preparation, or vice versa, with a wash out interval of two weeks. The plasma concentrations of secnidazole 
were determined by HPLC, and the samples were extracted with tert-butyl-methyl-ether: dicloromethane 
(60:40, v/v). Secnidazole and its parent compound metronidazole were separated on a C18 column with 
water:acetonitrile (85:15, v/v) as the mobile phase, and monitored at 310 nm. The ratio of mean C
max
, 
AUC
0−t
 and AUC
0−∞
 values for the test and reference products were within the predetermined range 
established by ANVISA, demonstrating that the two formulations are bioequivalent in rate and extent 
of absorption.
Uniterms: Oral formulas/bioequivalence study. Secnidazole/bioavailability. Antimicrobials/
bioavailability.
Secnidazol é um agente antimicrobiano utilizado principalmente no tratamento da amebíase. Para este 
estudo de bioequivalência de secnidazol em voluntários saudáveis, foram incluídos vinte e oito voluntárias 
mulheres no estudo randomizado cruzado. Cada voluntária recebeu uma única dose oral de secnidazol 
do produto teste e referência para comparação, com um intervalo de wash-out de duas semanas. As 
concentrações plasmáticas de secnidazol foram determinados por CLAE, as amostras foram extraídas 
com terc-butil-metil-éter: dicloromethano (60:40, v/v). O secnidazol e seu padrão interno metronidazol 
foram separados em uma coluna (C18 )  com fase móvel água ultra-pura:acetonitrila (85:15, v/v) e 
monitorado em 310 nm. As razões entre as médias geométricas de C
máx
, ASC
0-t
 e ASC
0-∞
, encontraram-
se dentro do estabelecido pela ANVISA, demonstrando que as formulações são bioequivalentes quanto 
à taxa e extensão de absorção
Unitermos: Formulações orais/estudo de bioequivalência. Secnidazol/biodisponibilidade. 
Antimicrobianos/biodisponibilidade.
INTRODUCTION
Nitroimidazoles have recently been indicated as the 
category of drugs offering the closest to ideal treatment 
for amoebiasis, due to their low toxicity (Silva, 2006). The 
principal derivatives of nitroimidazoles are: metronidazo-
le, tinidazole, ornidazole, and secnidazole, (Silva, 2006; 
Goodman et al., 2007).
These drugs share the same common spectrum of 
action against anaerobic microorganisms and are also 
effective in treatment of amoebiasis, giardiasis and tricho-
monas (Gillis et al., 1996).
Metronidazole was the first nitroimidazole for the 
treatment of trichomonas, a  disease caused by Trycho-
monas vaginalis, although there are now reports that 
secnidazole is more effective for curing disorders caused 
by this pathogen (Saracoglu et al., 1998).
Secnidazole is well absorbed orally (almost 100%) 
in healthy individuals, reaching a peak plasma level of 36 
to 46 µg/mL in 1.5 to 3 hours after a single dose of 2 g. 
Akin to metronidazole, secnidazole is transformed in the 
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liver, principally by oxidation, as it does not induce nor 
inhibit iso enzymes of CP
450
, and its principal metabolite 
while inactive is RP-35843. It has a plasma half life of 
17 to 29 hours in men and 14 hours in women (Klasco et 
al., 2006).
Studies of bioavailability and equivalence are used 
to determine the blood pharmaceutical concentration of 
the test pharmaceutical compared to the reference medi-
cation. Based on these studies, therapeutic equivalence is 
confirmed for the generic product, which represents a less 
costly alternative for the general population.
This study was designed to evaluate the bioavailabi-
lity of two medications containing secnidazole 1000 mg, to 
determine their bioequivalence. The test product, secnida-
zole 1000 mg, was obtained from Prati, Donaduzzi Labo-
ratories, while the reference was secnidazole (Secnidal®) 
1000 mg from Adventis Pharma Laboratory.
MATERIAL AND METHODS
Material
Secnidazole 1000 mg, tablet form (test medication)
Secnidal® 1000 mg tablet form (reference medication)
Secnidazole (Study standard - Siddharth International)
Metronidazole (Internal standard-secondary standard- 
Aarti Drugs)
Reagents
Distilled water
Acetonitrile HPLC Grade (TEDIA)
Methyl-tert-butyl-ether (TEDIA)
Dichloromethane (TEDIA)
Equipments
High Performance Liquid Chromatography (HPLC) Soft-
ware LC Solution- Shimadzu®
Automatic pipettes EP 20, 200, 1000, and 5000 µL
Ultra Freezer, ILSHIN
Freezer, Electrolux FE26
Refrigerated Centrifuge, CIENTEC 5000R
Vortex Tube Agitator, AP 56 PHOENIX
Bain Marie- TECNAL
WinNolin Pharsight®
Volunteer Selection
Twenty-eight healthy female volunteers between the 
ages of 18 and 50 years, with a body mass index of ≥ than 
19 and ≤ 27 and no serious diseases were selected after a 
medical exam. Before the study, the volunteers underwent 
a clinical history, clinical exam, laboratory tests and elec-
trocardiogram.
All patients read and signed an informed consent 
statement before entering the study, which was approved 
by the Research Ethics Committee of the Hospital de Clí-
nicas in Curitiba, Paraná. 
The study involved two hospitalizations of 23 hours 
with a two-week interval. Volunteers were admitted to a 
private clinic, and were fasting for 8 hours before the study 
which began at 7 a.m. During the study, the volunteers re-
ceived a standard diet and had vital signs (blood pressure, 
pulse) and temperature monitored constantly.
The pre-dose blood sample was collected in a hepa-
rinized vacutainer about 60 minutes before the medication 
was given. Further blood samples were collected at the 
following times  after administration:  at one hour, then 
every 20 minutes for the next 6 samples, then half hourly 
for two samples, then at 4,6,10 48 and 96 hours after ad-
ministration  (corresponding to the following times:1:00; 
1:20;1:40;2:00; 2:40; 3:00; 3:30; 4:00; 6:00; 10:00; 48:00 
and 96:00 hours).
Samples were centrifuged at 3000 rpm for 10 mi-
nutes at 4 ºC, and the plasma was then transferred into 
cryogenic tubes and stored in a freezer at -20 ºC. After 
freezing, the samples were transported to the analytic 
laboratory.
Study Design
The study was a randomized open “crossover” 
consisting of two time periods, using a single oral dose 
for each administration and a washout period between ad-
ministrations. Patients were randomized to receive either 
the test drug followed by the reference drug or vice versa. 
Blood samples were collected to allow for at least three 
half-lives of the agent to elapse. A wash out period of two 
weeks was allowed to be certain of elimination of secni-
dazole 1000 mg, which has a half-life of about 21 hours.
Bioanalytical Methods
The bioanalytical method devised to quantify secni-
dazol levels in human plasma was validated by examining 
the following parameters, as set forth in Resolution N.899 
of May 29, 2003 (Brasil, 2003): specificity, linearity, recu-
peration, quantification limits, detection limit, precision 
and accuracy, robustness, and stability.
Plasma samples containing secnidazole were 
analyzed using High Performance Liquid Chromatography 
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(HPLC), with metronidazole as the internal standard. A 
total of 300 µL of plasma was transferred to an Eppendorf 
tube and 40 µL of standard solution (1000 ug/mL dissolved 
in acetonitrile 20%), was added, and the tubes then agitated 
in a vortex for 30 seconds.
Extraction was done using 4 mL of methyl-tert-
butyl-ether (60:40, v/v) and the tubes were spun for a 
further 90 seconds and then centrifuged at 2,700 rpm for 
20 minutes at 4 0C. After centrifugation, the organic phase 
was separated and evaporated under nitrogen at 45 °C 
until dry. The residue was reconstituted with 200 µL of 
acetonitrile 15%. The mobile phase was reconstituted with 
distilled water: acetonitrile (85:15). Analysis was done un-
der flux of 1.0 mL/min and volume of injection was 50 µL.
The HPLC system used was Shimadzu (Kyoto, 
Japan) model LC-20AT with a quaternary system of bom-
bardment and an automatic degasification module for the 
mobile phase.  Detection was done using UV at 310 nm. 
Chromatographic separation was done on a Kromasil C 
18 (150x4.6 mm, 5 µm).
Concentration calculations of the samples were done 
using the software LC Solution®, provided with the HPLC 
system. The ratio of the area of the peak of secnidazole 
and the internal standard metronidazole were used as the 
calibration curve, using a linear regression model with a 
weight of 1/x, for the straight line equation: y=ax + b, whe-
re y corresponds to the areas of secnidazole/metronidazole 
and x refers to the concentration of Secnidazole; b is the 
intersection of the line with the y axis and a corresponds 
to the slope of the line.
Pharmacokinetic Analysis
The maximum peak concentration (C
max
) and the time 
to attain this concentration (T
max
) were obtained directly 
from the details of plasma concentration versus time. The 
plasma half-life was found using the following equation: T
1/2
 
= 0.693/K
le
 , where the elimination constant (K
el
) was calcu-
lated from the inclination coefficient of the regression line 
adjusted for at least the last three concentration values in log 
n format. The area under the curve of concentration versus 
time, from time zero until the final collection (AUC
0-t
) was 
obtained using the method of trapezoids. The area under the 
curve from zero until infinity (AUC
0-∞
)
 
was calculated as fol-
lows: AUC
0-∞
= AUC
0-t
 + Ct/K
le
,where C
t
 is the last measured 
concentration (Chow et al., 2000).
Statistical Analysis
The pharmacokinetic parameters C
max
, AUC
0-t 
and
 
AUC
0-∞
, were analyzed after logarythmic transformation 
(In). ANOVA analysis of variance for crossover studies 
was used, as well as the details of Cmax, AUC
0-t
 and
 
AUC
0-∞
, to determine the effects of the sequence and vo-
lunteer within the sequence, formulation, and time period. 
A 90% Confidence Interval (CI) was used for the ra-
tio of the geomentric means of the transformed data for the 
test medication and the reference standard (test/reference). 
The two medications were considered bioequivalent when 
the 90% CI of the ratio of the means was between 80 and 
125% (Brasil, 2006).
RESULTS AND DISCUSSION
Twenty eight female volunteers with a mean age of 
28 years, mean weight of 59.05 kg, mean height of 1.61 m 
and mean BMI of 22.81, participated in the study. The 
following inclusion criteria were observed: healthy female 
volunteers, not pregnant and not nursing, with a Body 
Mass Index ≥ 19 and ≤27, willing to sign an informed 
consent form, and comply with the study protocol. The 
laboratory exams applied were: clinical history, physical 
and psychological examination, blood pressure and pulse, 
EEG and complementary laboratory exams. Subjects also 
had to be able to understand the nature and objective of 
the study and be willing to cooperate with the Investigator 
and adhere to all the study requirements.
The method used in the study has some advantages 
compared to other methods using HPLC, as described in 
the literature. Ravi and coauthors (1997) used dichloro-
methane as an extraction solvent, which led to some di-
fficulties in processing of the samples and in recuperation 
and accuracy of the results. In the present study, a strongly 
non-polar solvent, methyl-tert-butyl-ether (60:40, v/v) was 
used for extraction, improving processing conditions and 
results, while providing greater ease, speed and recupera-
tion during extraction of the samples.
In another bioanalytical method, Bibi et al. (2002) 
used ZnSO
4
 and NaOH in the extraction by precipitation, 
which yielded extracts with a greater number of impurities 
compared to liquid-liquid extraction. In the two studies 
cited above, the mobile phase consisted of acetonitrile: 
0.02 M sodium acetate (10:90 v/v) adjusted for pH and a 
chromatography column of 250 mm in length. However, 
the present study used a mobile phase of water: acetonitrile 
(87:13 v/v), which did not need pH adjustment and or an 
acetate buffer, which leads to marked wear in the chromato-
graphic column and compartments of the HPLC. Therefore, 
the method which we used is easier, more practical, precise 
and cost effective. The run time in this study was 6 minu-
tes, which is shorter than that used by Niadu et al. (1997) 
and Bibi et al. (2002). This short time was probably due to 
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the column length of 150 mm, which allowed analysis of 
a larger number of samples in a shorter time period, with 
greater economy of reagents, since bioequivalence studies 
usually involve an average of 1300 samples.
According to Ravi et al. (1997), in order to ob-
tain a quantification limit in a concentration less than 
1000 ng/mL, an electron capture detector should be used. 
However, in the current study a quantification limit of 
300 ng/mL was observed without the need for this detector.
The method employed in this study followed the 
legislation in force (Brasil, 2003) and the stability of the 
pharmacologic agent in plasma was also proven. The para-
meters of precision and accuracy yielded values of 6.37% 
and 100.21% for CBQ; 4.62% and 106.88% for CMQ and 
4.90% and 108.95% for CQA, respectively. For linearity, 
the value found was 0.9980, the angular coefficient was 
41697.07 and the line intercept was -16.3680. Recupera-
tion values were 99.22% for secnidazole and 85.58% for 
the internal standard metronidazole. The samples remained 
stable during the three cycles of freezing and thawing in 
the short-term of 4 hours, post-processing of 48 hours, 
and long-term of 56 days afterward, indicating adequate 
stability of the plasma samples of volunteers from the time 
of collection to the last analysis.
Figure 1 shows the chromatographic profile of 
secnidazole.
The analytic method used in this study for the quan-
tification of secnidazole in plasma samples can also be 
applied in bioequivalence studies.
The curve of mean plasma concentration versus 
time for the test medication and the reference is shown in 
Figure 2, demonstrating similar absorption, distribution 
and elimination for both drugs.
The pharmacologic parameters of the reference and 
test medications are shown in Table 1.
The plasma half-life (T
1/2
) of both products was simi-
lar, with a mean of 19.60 hours. In a similar study, Bibi et 
al. (2002) found a plasma half life of 13.86 hours; although 
Tenenbaum et al. (1993), in a study which used 2 g of 
secnidazole, found a greater half-life of 28.80 hours. The 
time taken to reach maximum concentration (T
max)
 in our 
study was. on average, 1.64 hours.  Bibi et al (2002) found 
a mean T
msx 
 of 1.77 whereas Shahid (2001) found a T
max
 of 
5.03 hours in male volunteers. The maximum mean con-
centration found in the present study was 24,899.32 ng/mL, 
above the value of 16,240.00 ng/mL found by Bibi et 
al. (2002). Ravi et al. (1997) however,  found a C
max
 of 
25,680.00 ng/mL in six male volunteers.
The ANOVA results for the parameters Cmax, 
AUC
0-96
 and AUC
0-∞
 shown in Table II demonstrate no 
significant difference in the formulations, period and 
sequence at a level of significance of a = 0.05, indicating 
equivalence of the bioavailability means of secnidal® and 
Secnidazole.
The difference found in effect of volunteer (se-
quence) for the parameters C
max
, AUC
0-96
 and AUC
0-∞
, 
reflects individual variability. The ratio of the geometric 
means for C
max
, was 99.46%, with a 90 %CI (Confidence 
FIGURE 1 - Chromatograph obtained from volunteers after administration of 1000 mg of secnidazole added to the internal standard, 
with retention times of 2.8 and 4.1 minutes, respectively. Chromatographic conditions: column C 18-Kromasil Akzo-Nobel, 150 mm 
x 4.6 mm; mobile phase consisted of distilled water and acetonitrile (85:15 v/v) with elution rate of 1 mL/min at a temperature of 
40 °C and UV detection of 310 nm.
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Interval) of 95.97% - 103.07%. For AUC
0-96, 
the ratio of 
geometric means was100.88% with a 90% CI of 97.98% 
-103.86%; and for AUC
0-∞
, the ratio was 99.71% with a 
90% CI of 96.59%-103.60%.
FIGURE 2 - Profile of mean plasma concentrations (± 2 standard errors) of secnidazole versus time, for one dose of the test and 
reference formulations of an oral dose of secnidazole 1000 mg.
TABLE 1 - Pharmacologic parameters of the reference standard 
and test medications 
Pharmacokinetic Parameter Secnidal® Secnidazole
T
max 
(h) 1.83 
(2.00)
1.45 
(1.08)Mean  (Standard Deviation)
C
max 
(ng/mL) 25,020.35 
(4101.64)
24,778.29 
(3329.89)Mean (Standard Deviation)
K
el 
(1/h) 0.04 
(0.01)
0.04 
(0.01)Mean (Standard Deviation)
T
1/2 
(h) 19.97 
(4.29)
19.23 
(3.35)Mean (Standard Deviation)
AUC
0-96 
(ng/mL.h) 676,436.39 
(103,797.75)
684,080.84 
(11,866.61)Mean (Standard Deviation)
AUC
0-∞ 
(ng/mL.h) 707,181.13 
(105,924.32)
707,925.29 
(124,391.66)Mean (Standard Deviation)
T
max
 =Time to reach maximum concentration; C
máx
 = Maximum 
concentration obtained; K
el
 =Elimination constant; T
1/2
 = Plasma 
elimination half-life; AUC
0-96
 =Area under the concentration 
curve versus time from 0 -96 hours; AUC
0-∞
 = Area under the 
concentration curve versus time extrapolated to infinity
TABLE II - Analysis of Variance (ANOVA) of the Pharmacokinetic 
Parameters
Parameter Treatment Statistic F P-Value
C
max Sequence 2.1677 0.1529
Volunteer 
(Sequence)
6.3184 0.0000*
Formulation 0.0668 0.7980
Period 0.1296 0.7217
AUC
0-96 Sequence 0.1849 0.6708
Volunteer 
(Sequence)
12.2485 0.0000*
Formulation 0.2634 0.6122
Period 0.6500 0.4274
AUC
0-∞ Sequence 0.2423 0.6267
Volunteer 
(Sequence)
9.7477 0.0000*
Formulation 0.0238 0.8785
Period 0.5191 0.4777
C
max
 =Maximum  Concentration; ASC
0-96
 = Area under the 
concentration curve versus time 0 to 96 hours; ASC
0-∞
 = Area 
under the concentration curve versus time extrapolated to 
infinity; * significant difference (p ≤ 0.05)
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The results of the analysis of variance with the 
Confidence Intervals for the above parameters prove the 
bioequivalence of the formulations, as the 90% CI of the 
ratio of means was between 80-125% (Brasil, 2006).
The power of the test used in this study was above 
99.99%, indicating that the number of volunteers in the 
study was sufficient to ensure reliability of the results.
CONCLUSION
The results of this study show that the two formula-
tions of Senidazole (test/reference) are interchangeable, 
as the 90% CI of the pharmacokinetic parameters evalu-
ated were within the range established by the regulatory 
agency-ANVISA.
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